CAR-T cell therapy for B-cell lymphoma that has returned or not responded
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma that is CD19-positive (a specific marker on the cancer cells).
- Your lymphoma must have not responded to second-line treatment, or come back after first-line treatment when no other curative options like stem cell transplant are available, or come back within one year of an autologous stem cell transplant.
- You must have at least one tumor that can be measured by standard imaging tests.
- You must be between 13 and 75 years old.
- Your organs (kidneys, liver, heart) must be working well enough, as shown by blood and heart tests.
- You must have enough healthy blood cells (neutrophils, hemoglobin, platelets).
- You must not have active lymphoma in the brain or spinal cord, active other cancers, severe organ failure, ongoing infections, HIV, active hepatitis B or C, or need strong immune-suppressing medicines for autoimmune disease.
- You cannot be pregnant or nursing, and both men and women must use two effective birth control methods if sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Hear when a new Relapsed/Refractory B-cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.